08:00 , Jan 11, 2016 |  BC Week In Review  |  Clinical News

Staccato alprazolam: Interim Phase IIa data

Interim data from 3 epileptics with acute repetitive seizures in a double-blind, crossover, U.S. Phase IIa trial showed that single doses of 0.5, 1 and 2 mg inhaled AZ-002 led to dose-related reductions in mean...
08:00 , Mar 3, 2008 |  BC Week In Review  |  Company News

Genisphere Inc., Invitrogen sales and marketing update

Invitrogen received exclusive rights to market fluorescent microRNA microarray labeling kits using Genisphere's 3DNA dendrimer signal amplification technology. Invitrogen is commercializing the technology as part of its NCode Rapid miRNA Labeling System. NCode is a...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Company News

Magen scientific advisory board update

Appointed: Alexa Kimball, director of the clinical unit for research trials in skin at Massachusetts General Hospital and Brigham and Women's Hospital at Harvard Medical School Magen BioSciences Inc., Cambridge, Mass.   Business: Dermatology  ...
08:00 , Dec 4, 2006 |  BC Week In Review  |  Company News

Caliper, Invitrogen deal

CALP partnered with IVGN's Molecular Probes Inc. subsidiary to develop and commercialize the VivoFluor 680 and 750 fluorescence labeling kits, which use IVGN's Alexa Fluor 680 and 750 dyes and are intended to be used...
08:00 , Nov 3, 2003 |  BC Week In Review  |  Company News

Invitrogen, Serologicals deal

SERO's Chemicon International Inc. (Temecula, Calif.) research division licensed Alexa Fluor fluorophores for labeling biologically active molecules from IVGN subsidiary Molecular Probes Inc. (Eugene, Ore.). Chemicon also acquired non-exclusive worldwide rights to distribute immunological reagents...
07:00 , Sep 1, 2003 |  BioCentury  |  Finance

Ebb & Flow

A horse kept in the stable too long can turn a measured trot into a mad sprint. Not one IPO has gotten done yet, but 10 companies are already in the queue, with about $800...
08:00 , Mar 24, 2003 |  BC Week In Review  |  Company News

Becton Dickinson sales and marketing update

BDX's BD Biosciences division launched flow cytometry products using Alexa Fluor dye technology from Molecular Probes Inc. (Eugene, Ore.). Becton Dickinson and Co. (BDX), Franklin Lakes, N.J.   Business: Supply/Service   ...
08:00 , Mar 31, 1997 |  BC Week In Review  |  Clinical News

Alexa 1000 device data

BZET announced preliminary results of two studies of Alexa 1000 to diagnose breast cancer by measuring electropotential differentials between points on the breast skin surface. The studies were presented at the Joint Meeting on Senology...
08:00 , Mar 3, 1997 |  BC Week In Review  |  Clinical News

Biofield regulatory update

The FDA did not accept for filing BZET's PMA for the Alexa 1000 System for breast cancer diagnosis, citing deficiencies in the application. BZET does not yet know whether it will be required to conduct...
08:00 , Jan 6, 1997 |  BC Week In Review  |  Clinical News

Biofield regulatory update

BZET filed a PMA with the FDA for its Alexa 1000 System for diagnosis of breast cancer. The FDA has granted expedited review status to the application. The PMA is based on clinical trials in...